ALT

$3.53

Post-MarketAs of Mar 17, 8:00 PM UTC

Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$3.53
Potential Upside
5%
Whystock Fair Value$3.71
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial ...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$442.07M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.17
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-50.57%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
18.35

Recent News

MarketBeat
Mar 12, 2026

Altimmune Touts Pemvidutide Progress, Targets MASH Phase 3 Start and Q3 AUD Readout at Barclays Chat

Altimmune (NASDAQ:ALT) executives highlighted clinical progress across multiple pemvidutide programs and discussed the company’s financing priorities during a Barclays fireside chat, with management pointing to upcoming catalysts in 2026 and a planned Phase 3 start in metabolic dysfunction-associate

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
MarketBeat
Mar 11, 2026

Altimmune Details Pemvidutide MASH Path: Breakthrough Therapy, FDA Feedback, Phase 3 Next Up

Altimmune (NASDAQ:ALT) executives highlighted recent clinical and regulatory milestones for pemvidutide and outlined plans to advance a Phase 3 program in metabolic dysfunction-associated steatohepatitis (MASH) during a presentation at the Leerink Partners Global Healthcare Conference. 2025 readout

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
MarketBeat
Mar 10, 2026

Altimmune Details Pemvidutide Phase III MASH Plans, Breakthrough Status at Citizens Conference

Altimmune (NASDAQ:ALT) executives used a presentation at the Citizens Life Sciences Conference to outline recent clinical results and development plans for pemvidutide, the company’s lead drug candidate being developed primarily for metabolic dysfunction–associated steatohepatitis (MASH). Chief Exec

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
Moby
Mar 6, 2026

Altimmune, Inc. Q4 2025 Earnings Call Summary

Moby summary of Altimmune, Inc.'s Q4 2025 earnings call

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
MarketBeat
Mar 5, 2026

Altimmune Q4 Earnings Call Highlights

Altimmune (NASDAQ:ALT) executives used the company’s year-end 2025 results call to outline preparations for a pivotal Phase 3 program for pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH), while also providing updates on ongoing Phase 2 studies in alcohol use disorder (AUD) and

BEARISH
Negative press. News cycle fixated on risk factors or misses.